Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: Influence of drug-drug interaction and patient characteristics

Journal of Clinical Pharmacology

Volumn 37, Issue 12, 1997, Pages 1160-1167

  Yukawa, Eiji ^a,c   To, Hideto ^a   Ohdo, Shigehiro ^a   Higuchi, Shun ^b   Aoyama, Toshinobu ^a  

^a Kyushu Universitay   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; PHENOBARBITAL; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CHILD; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; EPILEPSY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; ORAL DRUG ADMINISTRATION; POPULATION DYNAMICS; SYRUP; TABLET;

EID: 0031415157     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04301.x     Document Type: Article

References (23)

1. Schobben F, Van Der Kleijn E, Gabreels FJM: Pharmacokinetics of di-n-propylacetate in epileptic patients. Eur J Clin Pharmacol 1975;8:97-105.
2. Chiba K, Suganuma T, Ishizaki T, Iriki T, Shirai Y, Naitoh H, Hori M: Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. J Pediatr 1985;106:653-658.
3. Cloyd JC, Kriel RL, Fischer JH: Valproic acid pharmacokinetics in children. II. Discontinuation of concomitant antiepileptic drug therapy. Neurology 1985;35:1623-1627.
4. Hall K, Ölten N, Johnston B, Irvine-Meek J, Leroux M, Seshia S: A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics. J Clin Pharmacol 1985:25:261-268.
5. Perucca E, Gatti G, Frigo GM, Crema E, Calzetti S, Visintini D: Disposition of sodium valproato in epileptic patients. Br J Clin Pharmacol 1978; 5:495-499.
6. Bowdle TA, Levy AH, Cutler RE: Effects of carbamazepine on valproic acid kinetics in normal subjects. Clin Pharmacol Ther 1979:26:629-634.
7. Schapel GJ, Deran RG, Doecke CJ, O'Reilly W, Recce P, Rischbieth R, Samson L, Stanley P: Pharmacokinetics of sodium valproate in epileptic patients: prediction of maintenance dosage by single-dose study. Eurf Clin Pharmacol 1980;17:71-77.
8. Béai SL, Sheiner LB. (Eds). NÖNMEM Users Guides. NONMEM Project Group, University of California at San Francisco, San Francisco, 1992.
9. Yukawa E, Higuchi S, Aoyama T: Phenobarbitone population pharmacokinetics from routine clinical data: Role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol 1992:44:755-760.
10. Yukawa E: A feasibility study of the multiple-peak approach for pharmacokinetic screening: Population-based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data. }Pharm Pharmacol 1995;47:1048-1052.
11. Yukawa E, Aoyama T: Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinotic data. J Clin Pharmacol 1996;36:752-759.
12. Cloyd JC, Fischer JH, Kriel RL, Kraus DM: Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther 1993:53:22-29.
13. Gram L, Flachs H, Wurtz-Jorgonsen A, Parnas J, Anderson B. Sodium valproate, serum level and clinical effect in epilepsy: A controlled study. Epilepsia 1979:20:303-312.
14. May T, Rambeck B: Serum concentrations of valproic acid: Influence of dose and comedication. Ther Drug Monit 1985:7:387-390.
15. Bourgeois BFD: Pharmacological interactions between valproate and other drugs. Am J Med 1988;84(Suppl. 1A):29-33.
16. Levy RH, Koch KM: Drug interactions with valproic acid: Drugs 1982;24:543-55G.
17. Richard DS, Richard HM: Valproic acid: Interaction with other drugs. In: Levy RH, Mattson RH, Meldrum BS. (eds) Antiepileptic Drugs, Fourth Edition. Raven Press, Ltd., New York, 1995; pp 621-631.
18. Sackellares JC, Sato S, Dreifuss FE, Penry JK: Reduction of steady-state valproate levels by other antiepileptic drugs. Epilepsia 1981;22:437-441.
19. Mihaly GW, Vajda FJ, Miles JL, Louis WJ: Single and chronic dose pharmacokinetic studies of sodium valproate in epileptic patients. EurJClin Pharmacol 1979:16:23-29.
20. Reunanen MI, Luoma P, Myllyla VV, Hokkanen E: Low serum valproic acid concentrations in epileptic patients on combination therapy. Curr Ther Res Clin Exp 1980;28:45G-462.
21. Levy RH, Rettenmeier AW, Anderson GD, Wilensky AJ, Friel PN, Baillie TA, Acheampong A, Tor J, Guyot M, Loiseau P: Effects of polytherapy with phenytoin, carbamazepine, and stripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990;48:225-235.
22. Jann MW, Fidone GS, Israel MK, Bonadero P: Increased valproate serum concentrations upon carbamazepine cessation. Epilepsia 1988:29:578-581.
23. Henriksen O, Johannessen SI: Clinical and pharmacokinetic observations on sodium valproate- a 5-year follow-up study in 100 children with epilepsy. Acta Neural Scand 1982; 65:504-523.